# DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant

> **NCT03208244** · PHASE4 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 40 (actual)

## Conditions studied

- End Stage Heart Disease
- Hepatitis C

## Interventions

- **DRUG:** Clinically prescribed direct acting antiviral

## Key facts

- **NCT ID:** NCT03208244
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-09
- **Primary completion:** 2021-04-20
- **Final completion:** 2021-04-28
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Protocol transitioned to standard of care, no funding available to support research work
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03208244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03208244, "DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03208244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*